Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status
Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status
复制标题
DOI：
10.1093/annonc/12.suppl_2.s141
复制
发表时间：
2001-01-01
影响因子：
50.5
通讯作者：
Bonkhoff, H
中科院分区：
文献类型：
--
作者：
Bonkhoff, H
背景资料：神经内分泌（neuroendocrine，NE）分化在常见前列腺恶性肿瘤中的频繁发生，在当代前列腺癌研究中引起越来越多的关注。方法：本综述着重于NE表型的生长特性和雄激素受体（androgen receptor，AR）状态，并讨论它们在良性和恶性前列腺组织中的形态发生起源。最近的数据已经证明了NE细胞和良性和恶性前列腺组织中遇到的其他细胞谱系之间的表型联系。NE肿瘤细胞（如由最常用的内分泌标志物嗜铬粒蛋白A定义的）不增殖或显示凋亡活性。这种特殊的表型也缺乏核AR在良性和恶性conditions.Conclusions：前列腺NE细胞最有可能来自当地的干细胞和终末分化和雄激素不敏感的细胞群体在良性前列腺组织。前列腺癌中NE分化的频繁发生明显反映了其干细胞的分化库。缺乏核AR的肿瘤性NE细胞构成前列腺癌中的雄激素不敏感细胞群。NE肿瘤细胞缺乏增殖和凋亡活性，这可能使其对细胞毒药物和放射治疗具有相对抗性。
Background: The frequent occurrence of neuroendocrine (NE) differentiation in common prostatic malignancies has attracted increasing attention in contemporary prostate cancer research.Methods: The present review focuses on growth properties and the androgen receptor (AR) status of NE phenotypes, and discusses their morphogenetic origin in benign and malignant prostate tissue.Results: Recent data have documented a phenotype link between NE cells and other cell lineages encountered in benign and malignant prostate tissue. NE tumor cells (as defined by the most commonly used endocrine marker chromogranin A) do not proliferate or show apoptotic activity. This particular phenotype also lacks the nuclear AR in both benign and malignant conditions.Conclusions: Prostatic NE cells most likely derive from local stem cells and represent terminally differentiated and androgen-insensitive cell populations in benign prostate tissue. The frequent occurrence of NE differentiation in prostatic adenocarcinoma obviously reflects the differentiation repertoire of its stem cells. Neoplastic NE cells devoid of nuclear AR constitute an androgen-insensitive cell population in prostate cancer. The absence of proliferative and apoptotic activity may endow NE tumor cells with relative resistance towards cytotoxic drugs and radiation therapy.